Telix Pharmaceuticals makes radiopharmaceuticals, drugs that pair a radioactive isotope with a targeting molecule so they can image or treat cancer, with its lead commercial products being Illuccix and Gozellix for prostate cancer imaging and Zircaix for kidney cancer imaging. The structural appeal is that these are diagnostic agents used to select and monitor patients for expensive therapies, which gives them a recurring, procedure-driven revenue base and a moat built on regulatory approvals and isotope supply logistics. Revenue growth of 22.3% is the headline number, and the near-term question is whether the company converts that top-line momentum into earnings, since its 9.7% operating margin and 7.4% ROE remain thin against a trailing P/E of 105.7 and a forward P/E of 140.8. At a 50/100 score and no index membership, the stock is priced for execution that the current margins do not yet show, so the case rests on whether operating leverage from the 47.6% gross margin arrives on schedule.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 11 Oct 2026, 00:00 CEST | ACCE price target | $11.00 | first publication | $11.21 |
| 8 Oct 2026, 00:00 CEST | Fair value | $1.82 | $1.79 | $10.78 |
| 5 Oct 2026, 00:00 CEST | Fair value | $1.79 | $1.77 | $10.55 |
| 1 Oct 2026, 00:00 CEST | Fair value | $1.77 | $1.83 | $11.34 |
| 26 Sept 2026, 00:00 CEST | Fair value | $1.83 | $1.58 | $11.31 |
| 23 Sept 2026, 00:00 CEST | Fair value | $1.58 | $1.69 | $11.31 |
| 18 Sept 2026, 00:00 CEST | Fair value | $1.69 | $1.88 | $11.83 |
| 12 Sept 2026, 00:00 CEST | Fair value | $1.88 | $1.96 | $11.90 |
| 7 Sept 2026, 00:00 CEST | Fair value | $1.96 | $2.00 | $11.94 |
| 4 Sept 2026, 00:00 CEST | Fair value | $2.00 | $1.95 | $11.45 |
Answered from Telix Pharmaceuticals Limited American Depositary Shares fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $9.15 | - | - | 95.4x | 7.4% | 55 | 41 |
| BAVA.CO Bavarian Nordic A/S | kr 247.40 | kr 257 | 4% below | 12.7x | 12.2% | 86 | 86 |
| BIOA-B.ST BioArctic AB (publ) | kr 300.00 | kr 259 | 16% above | 254.2x | 5.2% | 62 | 38 |
| CAMX.ST Camurus AB (publ) | kr 666.00 | kr 325 | 105% above | 58.8x | 15.9% | 90 | 55 |
| ZEAL.CO Zealand Pharma A/S | kr 226.00 | - | - | 5.8x | 16.3% | 90 | 51 |
| BIOCON.NS Biocon Limited | ₹323.50 | - | - | 97.7x | - | 67 | 52 |
| KRYS Krystal Biotech Inc. Common Stock | $311.50 | $153 | 104% above | 40.1x | 20.1% | 95 | 71 |
Where TLX ranks against its sector peers on each metric.